Yakira Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-120,756
| Closed | -$1.78M | – | 340 |
|
|
2024
Q1 | $1.78M | Buy |
120,756
+66,638
| +123% | +$936K | 0.54% | 61 |
|
|
2023
Q4 | $726K | Hold |
54,118
| – | – | 0.24% | 88 |
|
|
2023
Q3 | $667K | Sell |
54,118
-10,000
| -16% | -$121K | 0.18% | 100 |
|
|
2023
Q2 | $789K | Sell |
64,118
-8,000
| -11% | -$100K | 0.21% | 102 |
|
|
2023
Q1 | $886K | Sell |
72,118
-13,614
| -16% | -$160K | 0.22% | 106 |
|
|
2022
Q4 | $982K | Sell |
85,732
-30,089
| -26% | -$248K | 0.2% | 129 |
|
|
2022
Q3 | $434K | Hold |
115,821
| – | – | 0.06% | 219 |
|
|
2022
Q2 | $689K | Buy |
115,821
+27,138
| +31% | +$153K | 0.11% | 193 |
|
|
2022
Q1 | $561K | Buy |
88,683
+15,233
| +21% | +$85.6K | 0.08% | 225 |
|
|
2021
Q4 | $287K | Buy |
73,450
+12,816
| +21% | +$55.6K | 0.04% | 275 |
|
|
2021
Q3 | $293K | Hold |
60,634
| – | – | 0.05% | 249 |
|
|
2021
Q2 | $387K | Hold |
60,634
| – | – | 0.06% | 237 |
|
|
2021
Q1 | $381K | Hold |
60,634
| – | – | 0.08% | 220 |
|
|
2020
Q4 | $418K | Sell |
60,634
-6,300
| -9% | -$31.1K | 0.1% | 177 |
|
|
2020
Q3 | $268K | Hold |
66,934
| – | – | 0.08% | 161 |
|
|
2020
Q2 | $223K | Hold |
66,934
| – | – | 0.1% | 109 |
|
|
2020
Q1 | $144K | Hold |
66,934
| – | – | 0.05% | 113 |
|
|
2019
Q4 | $211K | Hold |
66,934
| – | – | 0.06% | 116 |
|
|
2019
Q3 | $301K | Sell |
66,934
-18,139
| -21% | -$90.6K | 0.09% | 110 |
|
|
2019
Q2 | $405K | Hold |
85,073
| – | – | 0.08% | 104 |
|
|
2019
Q1 | $465K | Hold |
85,073
| – | – | 0.13% | 86 |
|
|
2018
Q4 | $258K | Hold |
85,073
| – | – | 0.09% | 92 |
|
|
2018
Q3 | $357K | Hold |
85,073
| – | – | 0.07% | 96 |
|
|
2018
Q2 | $329K | Sell |
85,073
-9,533
| -10% | -$63.3K | 0.08% | 88 |
|
|
2018
Q1 | $599K | Sell |
94,606
-12,119
| -11% | -$100K | 0.14% | 73 |
|
|
2017
Q4 | $861K | Buy |
106,725
+87,143
| +445% | +$813K | 0.28% | 53 |
|
|
2017
Q3 | $224K | Sell |
19,582
-12,295
| -39% | -$129K | 0.07% | 83 |
|
|
2017
Q2 | $311K | Buy |
31,877
+303
| +1% | +$6.19K | 0.09% | 83 |
|
|
2017
Q1 | $765K | Buy |
+31,574
| New | +$790K | 0.27% | 63 |
|
Other funds holding MACK
RA
JC
Yakira Capital Management's MACK Position: Q2 2024 in Review
Yakira Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 120,756 shares — an estimated $1.78M sold.
Yakira Capital Management first reported a position in MACK in Q1 2017 and held it in 29 quarters. The position peaked at $1.78M in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Yakira Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Yakira Capital Management sold 120,756 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.78M.
- Yakira Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 29 quarters.
- Yakira Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.78M in Q1 2024.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Yakira Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.